Literature DB >> 4001740

Persistence of vaccine-induced immune responses to rubella: comparison with natural infection.

D M Horstmann, A Schluederberg, J E Emmons, B K Evans, M F Randolph, W A Andiman.   

Abstract

Serologic responses and patterns of antibody persistence in children given HPV-77 DE-5 or RA27/3 vaccine were compared with those in children who had experienced natural infection. The results indicated that both vaccines induce long-lasting immunity in most individuals. RA27/3 vaccine proved more immunogenic and resulted in higher antibody titers; after 11 years 95% of those who seroconverted who were tested had hemagglutination-inhibiting (HAI) antibodies and 100% had neutralizing (NT) antibodies. Titers in HPV-77 DE-5 vaccinees were lower, and in 16% of those whose immune responses were feeble, HAI titers decreased to less than 1:8 after nine to 12 years; however, when their sera were examined by the more sensitive latex-agglutination test, all but two were found to have specific rubella antibody at levels of 1:1 to 1:16. Natural infection with wild virus was shown to induce more vigorous immune responses than did either vaccine: antibody titers were higher, decreases were smaller, and none fell to less than 1:8 (HAI) or less than 1:4 (NT).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4001740     DOI: 10.1093/clinids/7.supplement_1.s80

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

1.  Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA 27/3 in junior high school.

Authors:  Ching-Chiang Lin; Chun-Yuh Yang; Yung-Luen Shih; Yang-Yang Huang; Tsung-Han Yang; Jin-Yuan Liang; Chu-Fen Chang; Hsiu-Shu Hsieh; Yeou-Lih Huang
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

Review 2.  Rubella vaccines: past, present and future.

Authors:  J M Best
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

3.  SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine.

Authors:  Neelam Dhiman; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; Megan M O'Byrne; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Immunogenetics       Date:  2010-03-10       Impact factor: 2.846

Review 4.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 5.  Rubella vaccination.

Authors:  J Forster
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

6.  Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.

Authors:  Pritish K Tosh; Richard B Kennedy; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

7.  Recent rubella virus infection indicated by a low avidity of specific IgG.

Authors:  K Hedman; I Seppälä
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

8.  Immune responses to wild and vaccine rubella viruses after rubella vaccination.

Authors:  M G Cusi; R Metelli; P E Valensin
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks.

Authors:  Gaby Smits; Liesbeth Mollema; Susan Hahné; Hester de Melker; Irina Tcherniaeva; Sandra Waaijenborg; Rob van Binnendijk; Fiona van der Klis; Guy Berbers
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

10.  Conjunctivitis, the key clinical characteristic of adult rubella in Japan during two large outbreaks, 2012-2013 and 2018-2019.

Authors:  Hidetoshi Nomoto; Masahiro Ishikane; Takato Nakamoto; Masayuki Ohta; Shinichiro Morioka; Kei Yamamoto; Satoshi Kutsuna; Shunsuke Tezuka; Junwa Kunimatsu; Norio Ohmagari
Journal:  PLoS One       Date:  2020-04-24       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.